BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

857 related articles for article (PubMed ID: 28912154)

  • 21. p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.
    Hallows JL; Iosif RE; Biasell RD; Vincent I
    J Neurosci; 2006 Mar; 26(10):2738-44. PubMed ID: 16525053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Partial rescue of the p35-/- brain phenotype by low expression of a neuronal-specific enolase p25 transgene.
    Patzke H; Maddineni U; Ayala R; Morabito M; Volker J; Dikkes P; Ahlijanian MK; Tsai LH
    J Neurosci; 2003 Apr; 23(7):2769-78. PubMed ID: 12684463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity-dependent p25 generation regulates synaptic plasticity and Aβ-induced cognitive impairment.
    Seo J; Giusti-Rodríguez P; Zhou Y; Rudenko A; Cho S; Ota KT; Park C; Patzke H; Madabhushi R; Pan L; Mungenast AE; Guan JS; Delalle I; Tsai LH
    Cell; 2014 Apr; 157(2):486-498. PubMed ID: 24725413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.
    Boekhoorn K; Terwel D; Biemans B; Borghgraef P; Wiegert O; Ramakers GJ; de Vos K; Krugers H; Tomiyama T; Mori H; Joels M; van Leuven F; Lucassen PJ
    J Neurosci; 2006 Mar; 26(13):3514-23. PubMed ID: 16571759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adeno-associated virus 9-mediated Cdk5 inhibitory peptide reverses pathologic changes and behavioral deficits in the Alzheimer's disease mouse model.
    He Y; Pan S; Xu M; He R; Huang W; Song P; Huang J; Zhang HT; Hu Y
    FASEB J; 2017 Aug; 31(8):3383-3392. PubMed ID: 28420695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Actin interaction and regulation of cyclin-dependent kinase 5/p35 complex activity.
    Xu J; Tsutsumi K; Tokuraku K; Estes KA; Hisanaga S; Ikezu T
    J Neurochem; 2011 Jan; 116(2):192-204. PubMed ID: 20492361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature.
    Przybyla M; van Eersel J; van Hummel A; van der Hoven J; Sabale M; Harasta A; Müller J; Gajwani M; Prikas E; Mueller T; Stevens CH; Power J; Housley GD; Karl T; Kassiou M; Ke YD; Ittner A; Ittner LM
    Brain; 2020 Jun; 143(6):1889-1904. PubMed ID: 32375177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.
    Zheng YL; Li BS; Amin ND; Albers W; Pant HC
    Eur J Biochem; 2002 Sep; 269(18):4427-34. PubMed ID: 12230554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles.
    Tandon A; Yu H; Wang L; Rogaeva E; Sato C; Chishti MA; Kawarai T; Hasegawa H; Chen F; Davies P; Fraser PE; Westaway D; St George-Hyslop PH
    J Neurochem; 2003 Aug; 86(3):572-81. PubMed ID: 12859671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic distribution of CDK5 mRNA and p35 mRNA, and a glutamate-responsive increase of CDK5/p25 complex contribute to tau hyperphosphorylation.
    Tanaka T; Ohashi S; Takashima A; Kobayashi S
    Biochim Biophys Acta Gen Subj; 2022 Jul; 1866(7):130135. PubMed ID: 35358667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.
    Kesavapany S; Zheng YL; Amin N; Pant HC
    Biotechnol J; 2007 Aug; 2(8):978-87. PubMed ID: 17526058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation.
    Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
    Biochem Biophys Res Commun; 2002 Nov; 298(5):693-8. PubMed ID: 12419309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDK5 activator protein p25 preferentially binds and activates GSK3β.
    Chow HM; Guo D; Zhou JC; Zhang GY; Li HF; Herrup K; Zhang J
    Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4887-95. PubMed ID: 25331900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.
    Li G; Faibushevich A; Turunen BJ; Yoon SO; Georg G; Michaelis ML; Dobrowsky RT
    J Neurochem; 2003 Jan; 84(2):347-62. PubMed ID: 12558997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulforaphene, a CDK5 Inhibitor, attenuates cognitive deficits in a transgenic mouse model of Alzheimer's disease via reducing Aβ Deposition, tau hyperphosphorylation and synaptic dysfunction.
    Yang W; Xu QQ; Yuan Q; Xian YF; Lin ZX
    Int Immunopharmacol; 2023 Jan; 114():109504. PubMed ID: 36508924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of cyclin-dependent kinase-5 activity on apoptosis and tau phosphorylation in immortalized mouse brain cortical cells.
    Shelton SB; Krishnamurthy P; Johnson GV
    J Neurosci Res; 2004 Apr; 76(1):110-20. PubMed ID: 15048935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The inhibition of Cdk5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats.
    Tan X; Chen Y; Li J; Li X; Miao Z; Xin N; Zhu J; Ge W; Feng Y; Xu X
    Neuroscience; 2015 Apr; 290():552-60. PubMed ID: 25665755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.
    Zhang X; Hernandez I; Rei D; Mair W; Laha JK; Cornwell ME; Cuny GD; Tsai LH; Steen JA; Kosik KS
    J Biol Chem; 2013 Jul; 288(30):22042-56. PubMed ID: 23737518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo.
    Nikkel AL; Martino B; Markosyan S; Brederson JD; Medeiros R; Moeller A; Bitner RS
    Neuropharmacology; 2012 Sep; 63(4):606-12. PubMed ID: 22613839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant Tau knock-in mice display frontotemporal dementia relevant behaviour and histopathology.
    Koss DJ; Robinson L; Drever BD; Plucińska K; Stoppelkamp S; Veselcic P; Riedel G; Platt B
    Neurobiol Dis; 2016 Jul; 91():105-23. PubMed ID: 26949217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.